Tag: clinical trials
-
Early Trial Shows Pneumonia Vaccine Safety, Immune Response
23 June 2014. An early-stage clinical trial testing a vaccine by Genocea Biosciences Inc. to prevent pneumonia and related bacterial diseases shows the vaccine caused no serious side effects and induced more immune system cells to prevent these infections. The Cambridge, Massachusetts biotechnology company says it plans to present the findings at a medical conference…
-
Portfolio Model Proposed for Funding Alzheimer’s Research
18 June 2014. Financial and biomedical researchers at Massachusetts Institute of Technology, University of California in Santa Barbara, and the biotechnology company Genentech outlined a different approach to funding research on Alzheimer’s disease that supports multiple simultaneous studies addressing various drug targets. The team led by MIT finance professor Andrew Lo published its findings today…
-
FDA Grants Experimental Leukemia Drug Orphan Status
16 June 2014. Agios Pharmaceuticals Inc. in Cambridge, Massachusetts says the U.S. Food and Drug Administration designated its therapy for acute myelogenous leukemia an orphan drug, qualifying it for tax incentives and other benefits. The orphan drug status comes at the same time of new findings reported from an early clinical trial of the drug,…
-
Trial Shows Single-Dose Antibiotic Effective with MRSA
5 June 2014. Researchers at Duke University in Durham, North Carolina and the Medicines Company in Parsippany, New Jersey show in a late-stage clinical trial that a single dose of the antibiotic oritavancin works as well in treating acute bacterial skin infections, including those from methicillin-resistant Staphylococcus aureus (MRSA) bacteria, as the current standard of care…
-
Clinical-Stage Biotech Lands $15M in Early Venture Funding
4 June 2014. Trevi Therapeutics Inc., a biotechnology company in New Haven, Connecticut developing therapies for chronic itching conditions, secured $15 million in its second venture financing round. The funding, the first installment in a projected $25 million round, was led by current investor TPG Biotech and includes current angel investors in the company. Trevi…
-
Remote Heart Failure Monitoring Device Approved by FDA
29 May 2014. The U.S. Food and Drug Administration yesterday approved an implanted device that measures pulmonary artery pressure and heart rate of patients with moderate heart failure who were hospitalized in the previous year. The device, the CardioMEMS HF System, is made by CardioMEMS Inc. in Atlanta. St. Jude Medical, a medical device manufacturer…
-
Ohio State, Cancer Center Partner on Research Database
28 May 2014. Moffitt Cancer Center in Tampa and Ohio State University’s Comprehensive Cancer Center in Columbus are launching a repository of patient data and tumor samples to speed development of therapies and better match patients to clinical trials. Financial details of the Oncology Research Information Exchange Network or Orien created by the collaboration were…
-
Five Pharma Companies to Share Clinical Researcher Data
27 May 2014. Five pharmaceutical companies are joining together to share their files on researchers conducting clinical trials, to speed the administrative process of starting up new studies. The Investigator Databank is a joint project of Novartis, Janssen (a division of Johnson & Johnson), Merck, Eli Lilly and Co., and Pfizer, and administered by DrugDev,…
-
Drug Sensitivity Target Identified for Mesothelioma Therapy
27 May 2014. Researchers at the biopharmaceutical company Verastem Inc. in Cambridge, Massachusetts found the loss of a certain tumor suppressor improves responsiveness to therapies targeting cancer stem cells that treat mesothelioma, an aggressive form of lung cancer. The team led by Verastem’s research director Jonathan Pachter, with colleagues from Fox Chase Cancer Center in…
-
Engineered Antibody Given FDA Breakthrough Tag for Myeloma
19 May 2014. Bristol-Myers Squibb in New York says its engineered antibody elotuzumab received a breakthrough therapy designation from the U.S. Food and Drug Administration to treat multiple myeloma, when used with two other cancer drugs. Elotuzumab is being developed by Bristol-Myers Squibb and AbbVie, in North Chicago, Illinois. Multiple myeloma is a progressive cancer…